27 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
not successfully or efficiently manage our transition to operating a CAP-accredited and CLIA-certified laboratory subject to significant regulatory oversight … , reputational harm, diminished profits, additional reporting requirements, and oversight if we become subject to a corporate integrity agreement
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
a CAP-accredited and CLIA-certified laboratory subject to significant regulatory oversight and reporting obligations. However, to ease the transition … reporting requirements, and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non
424B5
d3bdyo
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
i50pkf7dwiyxxtqt
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
93x4o27ozctosarzlgo
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
pan1yjew
16 Nov 23
Shelf registration
5:23pm
8-K
EX-10.3
jv2mcf6b861
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
DRS
uy5hgd7cslwnf4cp
14 Aug 23
Draft registration statement
12:00am
DEF 14A
fjzu0zum3gzmh jqhd6
1 May 23
Definitive proxy
2:55pm
PRE 14A
lg3 i7bis1nmef
19 Apr 23
Preliminary proxy
9:56pm
10-K
034xcwhhow1sn nls
31 Mar 23
Annual report
3:40pm
10-Q
u75na68jmtti
14 Nov 22
Quarterly report
5:11pm